本页面由Tiger Trade Technology Pte. Ltd.提供服务

Seres Therapeutics, Inc.

6.81
+0.00180.03%
成交量:6.38万
成交额:42.92万
市值:6,596.50万
市盈率:-1.32
高:7.10
开:6.80
低:6.52
收:6.81
52周最高:29.98
52周最低:5.31
股本:968.39万
流通股本:738.18万
量比:0.96
换手率:0.86%
股息:- -
股息率:- -
每股收益(TTM):-5.1698
每股收益(LYR):0.0175
净资产收益率:-121.87%
总资产收益率:-38.88%
市净率:2.49
市盈率(LYR):389.18

数据加载中...

公司资料

公司名字:
Seres Therapeutics, Inc.
交易所:
NASDAQ
成立时间:
2010
员工人数:
66
公司地址:
101 Cambridgepark Drive,Cambridge,Massachusetts,United States
邮编:
02140
电话:
传真:
- -
简介:
Seres Therapeutics, Inc.于2010年10月根据特拉华州法律注册成立。该公司是一家临床阶段的生物制药公司,专注于为医疗脆弱人群开发活体生物治疗产品。其研发管线针对感染及炎症和免疫疾病,并利用首个获得FDA批准的口服微生物组疗法VOWST的开发经验所建立的平台。

董事

名称
职位
Richard N. Kender
Executive Chair and Interim Chief Executive Officer
Claire M. Fraser
Independent Director
Dennis A. Ausiello
Independent Director
Kurt C. Graves
Independent Director
Robert Rosiello
Independent Director
Stephen Berenson
Independent Director
Willard H. Dere
Independent Director
Eric D. Shaff
Director

股东

名称
职位
Richard N. Kender
Executive Chair and Interim Chief Executive Officer
Kelly Brady
Executive Vice President, Chief Operating Officer
Marella Thorell
Executive Vice President, Chief Financial Officer
Matthew Henn
President and Chief Scientific Officer
Thomas J. DesRosier
Executive Vice President, Chief Legal Officer